Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Un essai clinique de phase 2b du YN001 chez des adultes atteints d'athérosclérose coronaire (PURIFY-TIMI 81)

3 novembre 2026 mis à jour par: Beijing Inno Medicine Co., Ltd.

Essai clinique de phase 2b randomisé, multicentrique, en double aveugle, en parallèle et contrôlé par placebo pour évaluer l'efficacité et la sécurité du YN001 chez les adultes atteints d'athérosclérose coronarienne

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Aperçu de l'étude

Description détaillée

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

Type d'étude

Interventionnel

Inscription (Estimé)

456

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • New South Wales
      • Penrith, New South Wales, Australie, 2750
        • Recrutement
        • Cannopy Clinical Research
        • Contact:
    • Queensland
      • Brisbane, Queensland, Australie, 4064
        • Recrutement
        • Core Research Group Pty Ltd.
        • Contact:
    • Victoria
      • Altona N., Victoria, Australie, 3025
        • Recrutement
        • Canopy Clinical Research
        • Contact:
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • Pas encore de recrutement
        • St. Boniface Hospital
        • Contact:
          • Shuangbo Liu
          • Numéro de téléphone: 204-237-2793
          • E-mail: sliu@sbgh.mb.ca
    • Ontario
      • London, Ontario, Canada, N5A 5A5
        • Pas encore de recrutement
        • London Health Sciences Centre
        • Contact:
      • North York, Ontario, Canada, M6B 3H7
        • Pas encore de recrutement
        • North York Diagnostic and Cardiac Centre
        • Contact:
      • Toronto, Ontario, Canada, M5B 1W8
        • Pas encore de recrutement
        • St. Michael's Hospital
        • Contact:
      • Vaughan, Ontario, Canada, L6A 4N9
        • Pas encore de recrutement
        • Cardiac Clinic
        • Contact:
    • Toronto
      • Toronto, Toronto, Canada, M5G 2N2
        • Pas encore de recrutement
        • Toronto General Hospital - University Health Network
        • Contact:
    • An
      • Hefei, An, Chine, 230022
        • Recrutement
        • The First Affiliated Hospital of Anhui Medical Unversity
        • Contact:
          • Jianlong Wang, MD
          • Numéro de téléphone: 0086-13681292304
          • E-mail: Wjlmll@sina.com
    • Anhui
      • Hefei, Anhui, Chine, 230001
        • Recrutement
        • Anhui Provincial Hospital
        • Contact:
          • Kangyu Chen, MD
          • Numéro de téléphone: 0086 18056005099
          • E-mail: ustccky@126.com
        • Chercheur principal:
          • Kangyu Chen, MD
        • Sous-enquêteur:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100035
        • Recrutement
        • Beijing Jishuitan Hospital
        • Chercheur principal:
          • Wei Liu, MD
        • Contact:
          • Qingwei Ji, MD
          • Numéro de téléphone: 0086 18376642655
          • E-mail: jqwl24@163.cou
        • Chercheur principal:
          • Qingwei Ji, MD
      • Beijing, Beijing Municipality, Chine, 100029
        • Recrutement
        • Anzhen Hospital
        • Contact:
        • Chercheur principal:
          • Yuyang Liu, MD
      • Beijing, Beijing Municipality, Chine, 101100
        • Pas encore de recrutement
        • Beijing Luhe Hospital
        • Contact:
    • Fujian
      • Fuzhou, Fujian, Chine, 350001
        • Recrutement
        • Fujian Medical University Union Hospital
        • Contact:
        • Chercheur principal:
          • Mingfang Ye, MD
        • Sous-enquêteur:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou, Gansu, Chine, 730030
        • Recrutement
        • The Second Hospital & Clinical Medical School Lanzhou University
        • Contact:
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510080
    • Heilongjiang
      • Daqing, Heilongjiang, Chine, 163316
        • Recrutement
        • Daqing People's Hospital
        • Contact:
      • Harbin, Heilongjiang, Chine, 150001
        • Recrutement
        • The First Affiliated Hospital of Harbin Medical University
        • Contact:
        • Chercheur principal:
          • Lu Fu, MD
        • Chercheur principal:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan, Hubei, Chine, 430071
        • Recrutement
        • Zhongnan Hospital of Wuhan University
        • Contact:
        • Chercheur principal:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha, Hunan, Chine, 410008
        • Recrutement
        • The Second Xiangya Hospital fo Central South University
        • Contact:
    • Jilin
      • Changchun, Jilin, Chine, 130033
        • Recrutement
        • The First Hospital of Jilin University
        • Chercheur principal:
          • Qian Tong, MD
        • Contact:
    • Liaoning
      • Shenyang, Liaoning, Chine, 110015
        • Recrutement
        • The People's Hospital of Liaoning Province
        • Chercheur principal:
          • Ying Liu, MD
        • Contact:
    • Shaanxi
      • Xi'an, Shaanxi, Chine, 710068
        • Recrutement
        • Shaanxi Provincial People's Hospital
        • Contact:
    • Shandong
      • Jinan, Shandong, Chine
        • Recrutement
        • Central Hospital Affiliated to Shandong First Medicial University
        • Contact:
          • Guohai Su, MD
          • Numéro de téléphone: 0086 19953193319
          • E-mail: gttstg@163.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200032
        • Recrutement
        • Fudan University-Zhongshan Hospital
        • Chercheur principal:
          • Junbo Ge, MD
        • Contact:
        • Sous-enquêteur:
          • Yuxiang Dai, MD
      • Shanghai, Shanghai Municipality, Chine, 200001
        • Recrutement
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • Contact:
        • Chercheur principal:
          • Jun Bu, MD
    • Sichuan
      • Chengdu, Sichuan, Chine, 610041
        • Recrutement
        • West China Hospital of Sichuan University
        • Contact:
        • Chercheur principal:
          • Yong He, MD
      • Chengdu, Sichuan, Chine, 610072
        • Recrutement
        • Sichuan Provincial People's Hospital
        • Contact:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chine, 300211
        • Recrutement
        • The Second Hospital of Tianjin Medical University
        • Contact:
        • Chercheur principal:
          • Tong Liu, MD
      • Tianjin, Tianjin Municipality, Chine, 300121
        • Recrutement
        • Tianjin People's Hospital
        • Chercheur principal:
          • Zhuhua Yao, MD
        • Contact:
          • Zhuhua Yao, MD
          • Numéro de téléphone: 0086 13902199877
          • E-mail: tjyzhpci@163.com
    • Zhejiang
      • Hangzhou, Zhejiang, Chine, 310006
        • Recrutement
        • Zhejiang Provincial People's Hospital
        • Contact:
      • Suzhou, Zhejiang, Chine, 215006
        • Recrutement
        • The First Affiliated Hospital of Soochow University
        • Contact:
      • Wenzhou, Zhejiang, Chine, 325000
        • Recrutement
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • Contact:
    • Alabama
      • Huntsville, Alabama, États-Unis, 35801-4312
        • Recrutement
        • Heart Center Research, LLC
        • Contact:
    • California
      • Covina, California, États-Unis, 91740
      • Lincoln, California, États-Unis, 95648
        • Pas encore de recrutement
        • Clinical Trials Research
        • Contact:
      • Los Alamitos, California, États-Unis, 90720
        • Pas encore de recrutement
        • University of California Irvine Medical Center - Cardiovascular Center
        • Contact:
      • Stanford, California, États-Unis, 94305-2200
        • Pas encore de recrutement
        • Stanford Health Care General Cardiology
        • Contact:
      • Torrance, California, États-Unis, 90502-2006
        • Recrutement
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • Contact:
    • Florida
      • Boca Raton, Florida, États-Unis, 33434
        • Pas encore de recrutement
        • Flourish Research - Boca Raton
        • Contact:
      • Hialeah, Florida, États-Unis, 33016-1895
        • Recrutement
        • New Generation of Medical Research, LLC.
        • Contact:
      • St. Petersburg, Florida, États-Unis, 33709
    • Georgia
      • Atlanta, Georgia, États-Unis, 30303-3049
        • Pas encore de recrutement
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • Contact:
    • Idaho
      • Meridian, Idaho, États-Unis, 83642
        • Pas encore de recrutement
        • St. Luke's Clinic - Idaho Cardiology Associates
        • Contact:
    • Illinois
      • Springfield, Illinois, États-Unis, 62781
        • Pas encore de recrutement
        • Southern Illinois University School of Medicine
        • Contact:
    • Kansas
      • Overland Park, Kansas, États-Unis, 66211-1215
        • Recrutement
        • Midwest Heart & Vascular Specialists, LLC
        • Contact:
          • Stephen Bloom, MD
          • Numéro de téléphone: 913-253-3000
          • E-mail: sbloom@kc.rr.com
    • Missouri
      • St Louis, Missouri, États-Unis, 63110-1032
        • Recrutement
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • Contact:
    • North Carolina
      • Raleigh, North Carolina, États-Unis, 27607
        • Pas encore de recrutement
        • NC Heart and Vascular Research, LLC
        • Contact:
      • Winston-Salem, North Carolina, États-Unis, 27104-3520
        • Pas encore de recrutement
        • Javara Inc. - Wake Forest University Health Sciences
        • Contact:
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45219
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73135
        • Pas encore de recrutement
        • South Oklahoma Heart Research, LLC
        • Contact:
    • Pennsylvania
      • Camp Hill, Pennsylvania, États-Unis, 17011
        • Recrutement
        • Capital Area Research, LLC - Camp Hill
        • Contact:
    • Texas
      • Amarillo, Texas, États-Unis, 79106
        • Recrutement
        • PharmaTex Research, LLC
        • Contact:
      • Carrollton, Texas, États-Unis, 75010
        • Pas encore de recrutement
        • Pulse Care Heart and Vascular
        • Contact:
      • Tomball, Texas, États-Unis, 77375
        • Pas encore de recrutement
        • DM Clinical Research - Dallas
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Expérimental: Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Comparateur placebo: Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Relative change from baseline in coronary NCPV at Week 13
Délai: Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Délai: From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Délai: From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Délai: From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Délai: From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Délai: From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Délai: From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Délai: From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
Délai: From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Délai: From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
Délai: From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
Délai: From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
Délai: From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
Délai: From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Directeur d'études: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

31 juillet 2026

Achèvement primaire (Estimé)

31 juillet 2027

Achèvement de l'étude (Estimé)

31 mars 2029

Dates d'inscription aux études

Première soumission

2 avril 2026

Première soumission répondant aux critères de contrôle qualité

2 avril 2026

Première publication (Réel)

9 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • YN001-203
  • IND 157167 (Identificateur de registre: Beijing Inno Medicine Co., Ltd.)

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner